Adma Biologics, Inc. (ADMA) — 8-K Filings

8-K Filings (23)

• 8-K Filing — May 4, 2026
• ADMA Biologics Files 8-K with Exhibits — Mar 27, 2026 Risk: low
  ADMA Biologics, Inc. filed an 8-K on March 27, 2026, reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). The
• ADMA Biologics Files 8-K on Security Holder Votes — Jun 4, 2025 Risk: low
  ADMA Biologics, Inc. filed an 8-K on June 4, 2025, to report on matters submitted to a vote of its security holders. The filing details the company's corporate
• ADMA Biologics Files 8-K Report — Apr 28, 2025 Risk: low
  On April 28, 2025, ADMA Biologics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific mate
• ADMA Biologics Files 8-K on Financials — Mar 3, 2025 Risk: low
  ADMA Biologics, Inc. filed an 8-K on March 3, 2025, reporting on its results of operations and financial condition. The filing also includes financial statement
• ADMA Biologics Files 8-K on Director Changes and Compensation — Feb 21, 2025 Risk: low
  On February 19, 2025, ADMA Biologics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing a
• ADMA Biologics Files 8-K on Financials — Jan 13, 2025 Risk: low
  On January 13, 2025, ADMA Biologics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, along
• ADMA Biologics Files 8-K: Board & Compensation Updates — Jan 2, 2025 Risk: low
  On December 30, 2024, ADMA Biologics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing a
• ADMA Biologics Files 8-K — Dec 20, 2024 Risk: low
  ADMA Biologics, Inc. filed an 8-K on December 20, 2024, reporting other events and financial statements. The filing does not contain specific details about new
• ADMA Biologics Reports Director Changes and Compensation Updates — Nov 21, 2024 Risk: medium
  On November 19, 2024, ADMA Biologics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing i
• ADMA Biologics Changes Auditors to BDO USA, LLP — Oct 31, 2024 Risk: low
  ADMA Biologics, Inc. filed an 8-K on October 31, 2024, to report a change in its certifying accountant. The company has dismissed PricewaterhouseCoopers LLP and
• ADMA Biologics Files 8-K for Disclosure — Oct 10, 2024 Risk: low
  On October 9, 2024, ADMA Biologics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No s
• ADMA Biologics Changes Independent Auditor — Oct 9, 2024 Risk: medium
  ADMA Biologics, Inc. announced on October 3, 2024, a change in its certifying accountant. The company has dismissed PricewaterhouseCoopers LLP as its independen
• ADMA Biologics Files 8-K with Financials — Aug 14, 2024 Risk: low
  On August 14, 2024, ADMA Biologics, Inc. filed an 8-K report. The filing primarily concerns the submission of financial statements and exhibits, with no other s
• ADMA Biologics Appoints New Directors, Adjusts Executive Pay — Jul 26, 2024 Risk: medium
  On July 24, 2024, ADMA Biologics, Inc. announced changes to its board of directors and executive compensation. Specifically, the company elected two new directo
• ADMA Biologics Files 8-K for Amendments and Exhibits — Jun 28, 2024 Risk: low
  On June 27, 2024, ADMA Biologics, Inc. filed an 8-K report to disclose information regarding amendments to its articles of incorporation or bylaws and financial
• ADMA Biologics Files 8-K on Shareholder Votes & Exhibits — Jun 4, 2024 Risk: low
  On June 4, 2024, ADMA Biologics, Inc. filed an 8-K report to disclose information regarding matters submitted to a vote of security holders and financial statem
• ADMA Biologics Files 8-K Report — May 17, 2024 Risk: low
  On May 17, 2024, ADMA Biologics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No spec
• ADMA Biologics Appoints New Chief Medical Officer — Apr 2, 2024 Risk: medium
  On April 1, 2024, ADMA Biologics, Inc. announced the appointment of Maria T. Palombini, M.D., as Chief Medical Officer. Dr. Palombini brings extensive experienc
• ADMA Biologics Files 8-K Report — Mar 11, 2024 Risk: low
  On March 11, 2024, ADMA Biologics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events o
• ADMA Biologics Files 8-K Report — Mar 5, 2024 Risk: low
  On March 4, 2024, ADMA Biologics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No spe
• ADMA Biologics Files 8-K on Other Events and Financial Exhibits — Feb 21, 2024 Risk: low
  ADMA Biologics, Inc. filed an 8-K on February 21, 2024, reporting on "Other Events" and "Financial Statements and Exhibits." The filing indicates that the compa
• ADMA Biologics Files 8-K on Operations & Financial Condition — Jan 8, 2024
  ADMA Biologics, Inc. filed an 8-K on January 8, 2024, to report on its results of operations and financial condition. This filing is a standard disclosure and d

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX